Current and Future Therapeutic Strategies for Limb Girdle Muscular Dystrophy Type R1: Clinical and Experimental Approaches

• Published in: Pathophysiology (Amsterdam) 2021-05, Vol.28 (2), p.238-249
• Main Authors: Şahin, İzem Olcay, Özkul, Yusuf, Dündar, Munis
• Format: Article
• Language: English
• Subjects: calpainopathy; CAPN3; LGMDR1; Review; therapy strategies
• ISSN: 1873-149X; 0928-4680; 1873-149X
• DOI: 10.3390/pathophysiology28020016

Limb girdle muscular dystrophy type R1 disease is a progressive disease that is caused by mutations in the gene and involves the extremity muscles of the hip and shoulder girdle. The CAPN3 protein has proteolytic and non-proteolytic properties. The functions of the CAPN3 protein that have been determined so far can be listed as remodeling and combining contractile proteins in the sarcomere with the substrates with which it interacts, controlling the Ca flow in and out through the sarcoplasmic reticulum, and regulation of membrane repair and muscle regeneration. Even though there are several gene therapies, cellular therapies, and drug therapies, such as glucocorticoid treatment, AAV- mediated therapy, CRISPR-Cas9, induced pluripotent stem cells, MYO-029, and AMBMP, which are either in preclinical or clinical phases, or have been completed, there is no final cure. Inhibitors and small molecules (tauroursodeoxycholic acid, salubrinal, rapamycin, CDN1163, dwarf open reading frame) targeting ER stress factors that are thought to be effective in muscle loss can be considered potential therapy strategies. At present, little can be done to treat the progressive muscle wasting, loss of function, and premature mortality of patients with LGMDR1, and there is a pressing need for more research to develop potential therapies.